Tuba N. Gide

3.7k total citations · 1 hit paper
22 papers, 1.7k citations indexed

About

Tuba N. Gide is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Tuba N. Gide has authored 22 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 16 papers in Immunology and 3 papers in Molecular Biology. Recurrent topics in Tuba N. Gide's work include Cancer Immunotherapy and Biomarkers (18 papers), CAR-T cell therapy research (12 papers) and Immunotherapy and Immune Responses (11 papers). Tuba N. Gide is often cited by papers focused on Cancer Immunotherapy and Biomarkers (18 papers), CAR-T cell therapy research (12 papers) and Immunotherapy and Immune Responses (11 papers). Tuba N. Gide collaborates with scholars based in Australia, United Kingdom and New Zealand. Tuba N. Gide's co-authors include Richard A. Scolyer, Georgina V. Long, James S. Wilmott, Alexander M. Menzies, Matteo S. Carlino, Camelia Quek, Robyn P.M. Saw, John F. Thompson, Alexander Guminski and Kirsten L. Todd and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Tuba N. Gide

19 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade

2019 412 citations Imran G. House, Peter Savas et al. Clinical Cancer Research profile →

Peers

Countries citing papers authored by Tuba N. Gide

Since Specialization

Citations

This map shows the geographic impact of Tuba N. Gide's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tuba N. Gide with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tuba N. Gide more than expected).

Fields of papers citing papers by Tuba N. Gide

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tuba N. Gide. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tuba N. Gide. The network helps show where Tuba N. Gide may publish in the future.

Co-authorship network of co-authors of Tuba N. Gide

This figure shows the co-authorship network connecting the top 25 collaborators of Tuba N. Gide. A scholar is included among the top collaborators of Tuba N. Gide based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tuba N. Gide. Tuba N. Gide is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Multiomic analysis of cutaneous squamous cell carcinoma (cSCC) and association with response to anti-PD1 therapy (PD1). 2025 ·Journal of Clinical Oncology ·(unknown), Tuba N. Gide, (unknown), Nurudeen A. Adegoke, (unknown), Alexander M. Menzies, Georgina V. Long, James S. Wilmott, (unknown)	0
2	Factors Associated With Implementation of Biomarker Testing and Strategies to Improve Its Clinical Uptake in Cancer Care: Systematic Review Using Theoretical Domains Framework 2025 ·JCO Precision Oncology ·Rehana A Salam, Kate Dunlop, Tuba N. Gide, James S. Wilmott, Andrea L. Smith, Anne Ε. Cust	0
3	Rational use of adjuvant anti-PD-1: Multi-omics model of recurrence in stage III melanoma. 2025 ·Journal of Clinical Oncology ·Tuba N. Gide, Nurudeen A. Adegoke, Michael Xie, (unknown), Grace H. Attrill, (unknown), Robyn P.M. Saw, Ismael A. Vergara, Matteo S. Carlino, Serigne Lo, Inês Pires da Silva, (unknown), Alexander M. Menzies, Richard A. Scolyer, Georgina V. Long, James S. Wilmott	1
4	Tissue-Based Profiling Techniques to Achieve Precision Medicine in Cancer: Opportunities and Challenges in Melanoma 2024 ·Clinical Cancer Research ·Tuba N. Gide, (unknown), Richard A. Scolyer, Georgina V. Long, James S. Wilmott	1
5	Stroma-infiltrating T cell spatiotypes define immunotherapy outcomes in adolescent and young adult patients with melanoma 2024 ·Nature Communications ·(unknown), Grace H. Attrill, Tuba N. Gide, Peter M. Ferguson, (unknown), Ping Shang, Ismael A. Vergara, Umaimainthan Palendira, Inês Pires da Silva, Matteo S. Carlino, Alexander M. Menzies, Georgina V. Long, Richard A. Scolyer, James S. Wilmott, Camelia Quek	4
6	Cross-platform comparison of immune signatures in immunotherapy-treated patients with advanced melanoma using a rank-based scoring approach 2023 ·Journal of Translational Medicine ·(unknown), Tuba N. Gide, Nurudeen A. Adegoke, Camelia Quek, (unknown), Alison J. Potter, Ellis Patrick, Robyn P.M. Saw, John F. Thompson, Andrew J. Spillane, Kerwin F. Shannon, Matteo S. Carlino, Serigne Lo, Alexander M. Menzies, Inês Pires da Silva, Georgina V. Long, Richard A. Scolyer, James S. Wilmott	6
7	Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies 2023 ·OncoImmunology ·Tuba N. Gide, Elizabeth C. Paver, (unknown), (unknown), Nurudeen A. Adegoke, Alexander M. Menzies, Inês Pires da Silva, James S. Wilmott, Georgina V. Long, Richard A. Scolyer	20
8	Classification of the tumor immune microenvironment and associations with outcomes in patients with metastatic melanoma treated with immunotherapies 2023 ·Journal for ImmunoTherapy of Cancer ·Nurudeen A. Adegoke, Tuba N. Gide, (unknown), Camelia Quek, Ellis Patrick, Matteo S. Carlino, Serigne Lo, Alexander M. Menzies, Inês Pires da Silva, Ismael A. Vergara, Georgina V. Long, Richard A. Scolyer, James S. Wilmott	16
9	Distinct pretreatment innate immune landscape and posttreatment T cell responses underlie immunotherapy-induced colitis 2022 ·JCI Insight ·(unknown), Felix Marsh‐Wakefield, Robert V. Rawson, Tuba N. Gide, Angela L. Ferguson, (unknown), Camelia Quek, Inês Pires da Silva, (unknown), (unknown), Neomal S. Sandanayake, Matteo S. Carlino, Geoffrey W. McCaughan, James S. Wilmott, Richard A. Scolyer, Georgina V. Long, Alexander M. Menzies, Umaimainthan Palendira	10
10	Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites 2022 ·Journal for ImmunoTherapy of Cancer ·(unknown), Robert V. Rawson, Serigne Lo, Tasnia Ahmed, Ismael A. Vergara, Tuba N. Gide, Grace H. Attrill, Matteo S. Carlino, Robyn P.M. Saw, John F. Thompson, Andrew J. Spillane, Kerwin F. Shannon, Brindha Shivalingam, Alexander M. Menzies, James S. Wilmott, Georgina V. Long, Richard A. Scolyer, Inês Pires da Silva	32
11	Validation of an Accurate Automated Multiplex Immunofluorescence Method for Immuno-Profiling Melanoma 2022 ·Frontiers in Molecular Biosciences ·(unknown), Tuba N. Gide, (unknown), Alison J. Potter, Camelia Quek, Angela Hong, Georgina V. Long, Richard A. Scolyer, James S. Wilmott	17
12	A biomarker-guided Bayesian response-adaptive phase II trial for metastatic melanoma: The Personalized Immunotherapy Platform (PIP) trial design. 2022 ·Journal of Clinical Oncology ·Serigne Lo, Tuba N. Gide, Maria Gonzalez, Inês Pires da Silva, Alexander M. Menzies, Matteo S. Carlino, Richard A. Scolyer, Stéphane Héritier, James S. Wilmott, Georgina V. Long	1
13	Abstract LB208: Obesity is associated with lower tumor oxidative phosphorylation (OXPhos) in metastatic melanoma (MM) 2021 ·Cancer Research ·Andrew W. Hahn, Mingchu Xu, Jun Li, Lauren E. Haydu, Muhammad Ali Khan, Tuba N. Gide, Alexander M. Menzies, Courtney W. Hudgens, Theodore S. Nowicki, Jeffrey E. Gershenwald, Antoni Ribas, Michael T. Tetzlaff, Alexander J. Lazar, (unknown), Jennifer A. Wargo, P. Andrew Futreal, Jianhua Zhang, Michael A. Davies, Jennifer L. McQuade	2
14	Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade breakdown → 2019 ·Clinical Cancer Research ·Imran G. House, Peter Savas, Junyun Lai, Amanda X. Y. Chen, Amanda J. Oliver, Zhi L. Teo, Kirsten L. Todd, Melissa A. Henderson, Lauren Giuffrida, Emma V. Petley, Kevin Sek, Sherly Mardiana, Tuba N. Gide, Camelia Quek, Richard A. Scolyer, Georgina V. Long, James S. Wilmott, Sherene Loi, Phillip K. Darcy, Paul A. Beavis	412
15	Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patients 2019 ·OncoImmunology ·Tuba N. Gide, Inês Pires da Silva, Camelia Quek, Tasnia Ahmed, Alexander M. Menzies, Matteo S. Carlino, Robyn P.M. Saw, John F. Thompson, Marcel Batten, Georgina V. Long, Richard A. Scolyer, James S. Wilmott	59
16	CD103+ Tumor-Resident CD8+ T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti–PD-1 Treatment 2018 ·Clinical Cancer Research ·Jarem Edwards, James S. Wilmott, Jason Madore, Tuba N. Gide, Camelia Quek, Annie Tasker, Angela L. Ferguson, Jinbiao Chen, Rehana Hewavisenti, Peter Hersey, Thomas Gebhardt, Wolfgang Weninger, Warwick J. Britton, Robyn P.M. Saw, John F. Thompson, Alexander M. Menzies, Georgina V. Long, Richard A. Scolyer, Umaimainthan Palendira	317
17	Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1–Based Immunotherapy 2018 ·Clinical Cancer Research ·Su Yin Lim, Jenny Lee, Tuba N. Gide, Alexander M. Menzies, Alexander Guminski, Matteo S. Carlino, Edmond J. Breen, Jean Yang, Shila Ghazanfar, Richard Kefford, Richard A. Scolyer, Georgina V. Long, Helen Rizos	271
18	Inter‐ and intrapatient heterogeneity of indoleamine 2,3‐dioxygenase expression in primary and metastatic melanoma cells and the tumour microenvironment 2018 ·Histopathology ·Tuba N. Gide, (unknown), Alexander M. Menzies, Peter M. Ferguson, Jason Madore, Robyn P.M. Saw, John F. Thompson, Georgina V. Long, James S. Wilmott, Richard A. Scolyer	14
19	Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma 2017 ·Clinical Cancer Research ·Tuba N. Gide, James S. Wilmott, Richard A. Scolyer, Georgina V. Long	313
20	Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients 2017 ·Modern Pathology ·Hojabr Kakavand, Louise Jackett, Alexander M. Menzies, Tuba N. Gide, Matteo S. Carlino, Robyn P.M. Saw, John F. Thompson, James S. Wilmott, Georgina V. Long, Richard A. Scolyer	183

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact